Measuring the Impact of Pharmacy Customer Loyalty on Health System Utilization and Readmission Rates

December 27, 2018

Quantifying the direct and indirect value that a business unit delivers to its parent health system has traditionally been difficult. In this case study, we discuss the impact of pharmacy customer loyalty on the Fairview Health Services system, and we introduce a new, data-driven methodology for measuring value. Our approach utilizes external, individual-level consumer data and predictive modeling, and may be extensible to other health systems and service lines. Carrot Health analyzed the patient populations of Fairview (1.81 million patients) and its pharmacy division (415,000 customers).

Spotlight

Cato Research

Cato Research (CATO) is an international regulatory and clinical contract research organization (CRO) that has been delivering successful outcomes for its clients for more than 25 years.

OTHER WHITEPAPERS
news image

A Brief Synopsis of Modern Randomization Methodologies and Technologies

whitePaper | December 9, 2022

Randomized, double-blind clinical trials are the gold standard for adequate and well-controlled studies in modern times. However, prior to the late 1940s, randomization and blinding were not used in medicine and as result, bias was common.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More
news image

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More
news image

Three Challenges Facing Study Start Up and the Low-Code Solution

whitePaper | December 22, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies, the sooner a new treatment can be available for patients.

Read More
news image

Understanding the true cost of transparency reporting

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

Read More

Spotlight

Cato Research

Cato Research (CATO) is an international regulatory and clinical contract research organization (CRO) that has been delivering successful outcomes for its clients for more than 25 years.

Events